Genetic Variants Detected Using Cell-Free DNA from Blood and Tumor Samples in Patients with Inflammatory Breast Cancer
Authors:
- Jennifer S. WinnJWJennifer S. Winn
- Zachary HasseZHZachary Hasse
- Michael SlifkerMSMichael Slifker
- Jianming PeiJPJianming Pei
- Sebastian M. Arisi-FernandezSASebastian M. Arisi-Fernandez
- Jacqueline N. TalarchekJTJacqueline N. Talarchek
- Elias ObeidEOElias Obeid
- Donald A. BaldwinDBDonald A. Baldwin
- Yulan GongYGYulan Gong
- Eric RossEREric Ross
- Massimo CristofanilliMCMassimo Cristofanilli
- R. Katherine AlpaughRAR. Katherine Alpaugh
Open Access
- 14 February 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (4) , 1290
Abstract
We studied genomic alterations in 19 inflammatory breast cancer (IBC) patients with advanced disease using samples of tissue and paired blood serum or plasma (cell-free DNA, cfDNA) by targeted next generation sequencing (NGS). At diagnosis, the disease was triple negative (TN) in eleven patients (57.8%), ER+ Her2- IBC in six patients (31.6%), ER+ Her2+ IBC in one patient (5.3%), and ER- Her2+ IBC in one other patient (5.3%). Pathogenic or likely pathogenic variants were frequently detected in TP53 (47.3%), PMS2 (26.3%), MRE11 (26.3%), RB1 (10.5%), BRCA1 (10.5%), PTEN (10.5%) and AR (10.5%); other affected genes included PMS1, KMT2C, BRCA2, PALB2, MUTYH, MEN1, MSH2, CHEK2, NCOR1, PIK3CA, ESR1 and MAP2K4. In 15 of the 19 patients in which tissue and paired blood were collected at the same time point, 80% of the variants detected in tissue were also detected in the paired cfDNA. Higher concordance between tissue and cfDNA was found for variants with higher allele fraction in tissue (AFtissue ≥ 5%). Furthermore, 86% of the variants detected in cfDNA were also detected in paired tissue. Our study suggests that the genetic profile measured in blood cfDNA is complementary to that of tumor tissue in IBC patients.Keywords
This publication has 55 references indexed in Scilit:
- Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNAClinical Cancer Research, 2016
- Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal FluidJournal of Clinical Oncology, 2016
- Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015Journal of the National Comprehensive Cancer Network, 2016
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasmaNature Communications, 2015
- Molecular subtypes in patients with inflammatory breast cancer; a single center experience.2015
- Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-RibosylationCancer Cell, 2013
- Analysis of Circulating Tumor DNA to Monitor Metastatic Breast CancerNew England Journal of Medicine, 2013
- International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatmentAnnals of Oncology, 2010
- Epidemiology of Inflammatory Breast Cancer (IBC)1Breast Disease, 2006
- Mutational analysis of BARD1 in familial breast cancer patients in JapanCancer Letters, 2003